Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Adult patients 18-80 years of age~* RA for ≥ 2 months;~* Receiving outpatient treatment~* Patients naive to, and considered to be candidates for, methotrexate treatment~Exclusion criteria:~* Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA~* Inflammatory joint disease other than RA, or other systemic autoimmune disorder~* Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16~* Surgery within 12 weeks of study~* Previous treatment with any approved or investigational biologic agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy~* Concurrent treatment with any biologic agent or DMARD other than methotrexate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (0.5 g x 2) + Methotrexate (Type: EXPERIMENTAL): Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
- Rituximab (1.0 g x 2) + Methotrexate (Type: EXPERIMENTAL): Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
- Placebo + Methotrexate (Type: PLACEBO_COMPARATOR): Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.~From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).